Abbott Q2 2026 earnings beat, raises full-year profit guidance - qz.com
Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.
Archived explainer. For the current picture see today's ABT page.
ABBOTT LABS (ABT) is drawing unusual attention today. Our newswire has captured 20 stories on ABT across 15 sources in the last 36 hours, with AI sentiment reading bullish (avg 67/100).
ABBOTT LABS stock is moving higher today, with shares up 5.7% to $99.84 as of the latest update. The primary driver of the move is the company’s second-quarter 2026 earnings report, which beat expectations and led to an upward revision of full-year profit guidance. The stock has gained 4.2% over the last eight sessions, reflecting strong investor reaction to the results and improved outlook.
Abbott Laboratories reported adjusted earnings of $1.31 per share for the second quarter of 2026, exceeding the consensus estimate of $1.28. The company also raised its full-year earnings guidance, citing strong performance across its business segments. The Diagnostics division led the way with a 41.8% quarter-over-quarter growth, while the Medical Devices segment continued to drive overall growth. Abbott maintained its sales outlook for the year, reinforcing confidence in its long-term trajectory. The results and guidance update have been widely covered in the financial media, with multiple outlets highlighting the earnings beat and upward revision.
The stock has shown a strong intraday performance, with shares climbing to a session high of 11% earlier in the day. This is the most significant gain for ABT since 2020. The recent insider transactions also provide a positive signal, as a director purchased shares on May 7. Additionally, unusual options activity has been noted, with a notable call premium of $117K recorded in the last 36 hours. This suggests increased bullish positioning among traders. Meanwhile, the stock has not seen any insider sales in the last 90 days, with one buy totaling $174K reported on June 18.
The stock is currently trading near its 52-week high, having not printed any fresh 52-week lows in the past week. Investors should continue to monitor the broader market reaction to Abbott’s updated guidance and the performance of its key business segments. While no earnings report is scheduled in the immediate future, coverage breadth remains strong with 20 stories from 15 sources in the last 36 hours.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.
The healthcare company posted adjusted earnings of $1.31 a share in the second quarter, topping Wall Street
The healthcare company posted adjusted earnings of $1.31 a share in the second quarter, topping Wall Street's estimate of $1.28
Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.
Abbott exceeded second-quarter earnings and revenue expectations, raised its 2026 earnings guidance and maintained its sales outlook as Medical Devices continued to drive growth.
Abbott Laboratories (ABT) stock rises as the company reports better-than-expected Q2 2026 financials and boosts its full-year outlook. Read more here.
Abbott Laboratories in charts: Diagnostics leads Q2 growth with 41.8% Q/Q jump; Nutrition lagging Y/Y
More on ABT: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier ABT move explainers: 2026-07-17 · 2026-07-16